TNF-like Ligand 1A is Associated with Progression and Prognosis of Human Gastric Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Oct 2

PMID 31571922

Citations 3

Authors

Yaxian Gao

Yuanyuan Wang

Xiao Wang

Yongwei Wang

Xiaoqing Zhang

Xun Sun

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to investigate the function of TNF-like ligand 1A (TL1A) in the tumorigenesis and progression of gastric cancer (GC).

Methods: RNA-seq gene expression and clinical information for GC patients were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) between GC tissue samples and normal controls were screened with the edgeR package. Identification of gene co-expression and functional enrichment analyses were performed with Pearson's correlation analysis and gene set enrichment analysis (GSEA), respectively. Lastly, survival analysis was performed using the Kaplan-Meier method with the log rank test.

Results: expression in GC tissue samples were significantly higher than that in normal controls (LogFC=1.07 and =8.90E-07). Moreover, 215 genes, co-expressed with , and 21 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were obtained. Next, the miRNA-lncRNA/mRNA network, comprising 7 miRNAs, 27 lncRNAs, and 21 mRNAs, was constructed based on key genes from intersections between co-expression analysis and GSEA. In addition, survival analysis results demonstrated that (=2.6e-07) was significantly associated with the overall survival (OS) of GC patients.

Conclusion: was involved in the tumorigenesis and progression of GC, and was significantly associated with the OS of GC patients.

Citing Articles

Identification and characterization of ferroptosis-related genes in therapy-resistant gastric cancer.

Yu J, Li H, Huang C, Chen H Medicine (Baltimore). 2024; 103(20):e38193.

PMID: 38758860 PMC: 11098190. DOI: 10.1097/MD.0000000000038193.

Comprehensive pathway-related genes signature for prognosis and recurrence of ovarian cancer.

Zhao X, He M PeerJ. 2020; 8:e10437.

PMID: 33344083 PMC: 7718801. DOI: 10.7717/peerj.10437.

The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative.

Karin N Front Immunol. 2020; 11:557586.

PMID: 33193327 PMC: 7649122. DOI: 10.3389/fimmu.2020.557586.

References

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Haridas V, Shrivastava A, Su J, Yu G, Ni J, Liu D . VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene. 1999; 18(47):6496-504. DOI: 10.1038/sj.onc.1203059. View

Deng W, Gu X, Lu Y, Gu C, Zheng Y, Zhang Z . Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis. 2012; 15(1):71-85. DOI: 10.1007/s10456-011-9244-y. View

Hyland P, Lin S, Hu N, Zhang H, Wang L, Su H . Genetic variants in fas signaling pathway genes and risk of gastric cancer. Int J Cancer. 2013; 134(4):822-31. PMC: 3858487. DOI: 10.1002/ijc.28415. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Levin I, Zaretsky M, Aharoni A . Directed evolution of a soluble human DR3 receptor for the inhibition of TL1A induced cytokine secretion. PLoS One. 2017; 12(3):e0173460. PMC: 5344418. DOI: 10.1371/journal.pone.0173460. View

Razzak M . Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. Nat Rev Clin Oncol. 2014; 11(9):499. DOI: 10.1038/nrclinonc.2014.138. View

Chew L, Pan H, Yu J, Tian S, Huang W, Zhang J . A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002; 16(7):742-4. DOI: 10.1096/fj.01-0757fje. View

Lun A, Chen Y, Smyth G . It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR. Methods Mol Biol. 2016; 1418:391-416. DOI: 10.1007/978-1-4939-3578-9_19. View

10.

Gigek C, Calcagno D, Rasmussen L, Santos L, Leal M, Wisnieski F . Genetic variants in gastric cancer: Risks and clinical implications. Exp Mol Pathol. 2017; 103(1):101-111. DOI: 10.1016/j.yexmp.2017.07.004. View

11.

Sethi G, Sung B, Aggarwal B . Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer. Adv Exp Med Biol. 2009; 647:207-15. DOI: 10.1007/978-0-387-89520-8_15. View

12.

Elsberger B, Paravasthu D, Tovey S, Edwards J . Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. J Cancer Res Clin Oncol. 2011; 138(2):327-32. DOI: 10.1007/s00432-011-1096-8. View

13.

Zhai Y, Yu J, Huang W, Wang Z, Hayes A, Lu J . Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer. 1999; 82(1):131-6. DOI: 10.1002/(sici)1097-0215(19990702)82:1<131::aid-ijc22>3.0.co;2-o. View

14.

Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E . Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. Oncotarget. 2015; 6(31):32061-74. PMC: 4741659. DOI: 10.18632/oncotarget.5201. View

15.

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

16.

Wu J, Jiang Y, Yang W, He Z, Meng S, Zhang Q . Dual function of RGD-modified VEGI-192 for breast cancer treatment. Bioconjug Chem. 2012; 23(4):796-804. DOI: 10.1021/bc2006576. View

17.

Zhang S, Yu D . Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2011; 33(3):122-8. PMC: 3675659. DOI: 10.1016/j.tips.2011.11.002. View

18.

Frankish A, Harrow J . GENCODE pseudogenes. Methods Mol Biol. 2014; 1167:129-55. DOI: 10.1007/978-1-4939-0835-6_10. View

19.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

20.

Zhang N, Sanders A, Ye L, Kynaston H, Jiang W . Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res. 2010; 30(1):87-95. View